HWHuaquan Wang

Huaquan Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Huaquan Wang has a total of 292 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sirolimus is associated with longer relapse-free survival than cyclosporine in autoimmune hemolytic anemia and evans syndrome: a retrospective cohort study

    by Yang Zhang, Jiajun Wan, Guanyu Luo, Ziying Zhang, Yuhong Wu, Hong Liu, Huaquan Wang, Wen Qu, Jia Song, Lijuan Li, et al.

  • Open Access

    Inhibitory effects of the bone marrow microenvironment on erythroid progenitors in pure red cell aplasia

    by Huiqin Zhang, Naibo Hu, Yansong Wei, Yumei Liu, Liyan Yang, Yingao Liang, Pu Tang, Mengyuan Liu, Xifeng Dong, Haiyue Niu, et al.

  • Open Access

    Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study

    by Wenya Liu, Yue Ren, Yingao Liang, Yumei Liu, Liyan Yang, Xifeng Dong, Limin Xing, Zonghong Shao, Rong Fu, Huaquan Wang

  • Open Access

    A survival prognostic model for high-risk myelodysplastic syndrome patients treated with decitabine

    by Yumei Liu, Haiyue Niu, Yansong Wei, Liyan Yang, Huijuan Jiang, Lijuan Li, Limin Xing, Zonghong Shao, Rong Fu, Huaquan Wang

    Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic disorders characterized by cytopenias, ineffective hematopoiesis, dysplasia of hematopoietic cells, and an increase...

  • Somatic Mutations and Mutation Burden Predict Treatment Response and Survival in Adult Acquired Pure Red Cell Aplasia

    by Liyan Yang, Huiqin Zhang, Yansong Wei, Haiyue Niu, Yumei Liu, Tian Zhang, Limin Xing, Zonghong Shao, Rong Fu, Huaquan Wang

    Immunosuppressive therapy (IST) is the standard treatment for acquired pure red cell aplasia (aPRCA), but predictors of treatment response and long‐term prognosis remain unclear. The clinical significance of somatic mutations in aPRCA is not fully understood. We retrospectively analyzed 69 adult aPRCA patients who underwent targeted next‐generation sequencing of 69 genes associated with clonal hematopoiesis and myeloid neoplasms. Somatic mutations, T‐cell receptor (TCR) gene rearrangements, treatment response at 6 months, overall survival (OS), and progression‐free survival (PFS) were evaluated. Somatic mutations were detected in 62.3% of patients, mainly in epigenetic regulators like DNMT3A and TET2 . Although mutations did not predict 6‐month response to IST, higher mutation burden was associated with worse treatment outcomes ( p = 0.01). TP53 and DNMT3A mutations were linked to shorter OS and PFS. Survival worsened with increasing mutation numbers, while mutations in TET2 , ASXL1 , GATA2 , and STAT3 had no significant effect. TCR gene rearrangements were common in large granular lymphocyte leukemia‐associated aPRCA but did not affect treatment response or survival. Somatic mutations are common in aPRCA and reflect clonal hematopoiesis. Mutation burden is a key determinant of IST response, while TP53 and DNMT3A mutations signal poorer long‐term outcomes. Mutational profiling may improve risk stratification and guide personalized management.


  • Open Access

    Immune‐Mediated Multilineage Cytopenias in Thymoma: A Retrospective Case Series

    by Naibo Hu, Yansong Wei, Weinan Lin, Xifeng Dong, Huaquan Wang

    Background: Thymoma is associated with diverse immune abnormalities, yet immune‐mediated multilineage cytopenias are exceedingly rare and poorly defined. Their clinical features, immunologic patterns, and treatment outcomes remain unclear. Methods: We retrospectively reviewed four adult patients with histologically confirmed thymoma and immune‐mediated cytopenias affecting ≥ 2 hematopoietic lineages at a tertiary hematology center. Clinical data, bone marrow morphology, immunologic studies, T‐cell receptor (TCR) clonality, cytogenetics, next‐generation sequencing (NGS), treatments, and outcomes were collected. Responses were assessed using standardized criteria for immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and autoimmune neutropenia (AIN). Results: The four patients (aged 44–75 years) showed heterogeneous temporal patterns, with cytopenias occurring either before thymoma diagnosis or years after thymectomy. Three had trilineage cytopenia and one had bicytopenia, with combinations of AIHA, ITP, AIN, and pure red cell aplasia. Bone marrow findings ranged from normal cellularity to erythroid aplasia. Two patients demonstrated clonal TCR rearrangement consistent with T‐LGL leukemia, and NGS identified mutations including TET1, EP300, and BCORL1. All received immunosuppressive therapy. Neutrophil and platelet counts responded earlier (1–2 months), whereas erythroid recovery was slower. Despite initial responses (2 CR, 2 PR), three patients relapsed and required additional therapy. After 10–84 months of follow‐up, one patient remained in CR and three in PR. Conclusions: Thymoma‐associated multilineage cytopenias are heterogeneous, frequently relapsing, and driven by complex T‐cell–mediated immune dysregulation. Comprehensive evaluation and individualized immunosuppressive therapy are essential for management.


  • Open Access

    The Immunoregulatory and Hematopoietic Effects of Momelotinib in a Murine Bone Marrow Failure Model

    by Yue Zhang, Huiqin Zhang, Naibo Hu, Liping Yang, Yumei Liu, Liyan Yang, Xifeng Dong, Huaquan Wang

    Background: Immune‐mediated bone marrow failure (AA) is characterized by T cell‐mediated destruction of hematopoietic stem and progenitor cells (HSPCs). The JAK–STAT signaling pathway plays a crucial role in regulating immune responses, and JAK inhibitors have shown potential in treating immune‐mediated disorders. This study investigates the effects of MMB, a JAK inhibitor, in a mouse model of immune‐mediated bone marrow failure to evaluate its impact on hematopoiesis and immune cell function. Methods: In this study, immune‐mediated AA was induced in B6D2F1 female mice through irradiation and lymphocyte infusion. The mice were treated with MMB monotherapy at doses of 6.25 and 12.5 mg/kg for 14 days. Peripheral blood cell counts, bone marrow cell counts, plasma cytokine levels, T lymphocyte subsets, Fas/FasL expression, and hematopoietic stem and progenitor cell (HSPC) levels were analyzed to assess the effects of MMB treatment on immune function and hematopoiesis. Results: MMB treatment exacerbated the reduction in peripheral blood cell counts in marrow failure mice and decreased bone marrow hematopoietic cell numbers. Concurrently, MMB also reduced cytokine levels. The treatment also led to a significant reduction in CD4 + T cells and Tregs in both the spleen and bone marrow, while the low‐dose MMB group exhibited a decrease in CD8+ T cell count. Additionally, MMB did not significantly improve HSPC levels, and a decrease in the more primitive LSK and LT‐HSC populations was observed. However, later‐stage stem and progenitor cells, such as ST‐HSCs, MPPs, and CMPs, showed an increase in numbers. The treatment also resulted in downregulation of Fas expression on non‐T cells, while FasL expression on lymphocytes increased. Conclusion: MMB treatment exacerbated peripheral blood cell reduction and impaired bone marrow hematopoiesis in the immune‐mediated AA mouse model. Although MMB modulated T lymphocyte subsets, it did not significantly improve hematopoietic stem and progenitor cell function. These findings highlight the need for further research to explore the potential and limitations of JAK inhibitors like MMB in the treatment of immune‐mediated bone marrow failure.

  • Open Access

    Cyclosporine A improves survival in lower-risk hypoplastic myelodysplastic syndromes: a single-center retrospective study from China

    by Yumei Liu, Liyan Yang, Yansong Wei, Wei Zhang, Huijuan Jiang, Lijuan Li, Limin Xing, Zonghong Shao, Rong Fu, Huaquan Wang

    Hypoplastic myelodysplastic syndrome (hMDS) is an uncommon MDS subtype, accounting for approximately 10-15% of cases, characterized by bone marrow hypocellularity, severe cytopenias, and features of immune dysregulation. Its clinical course overlaps with aplastic anemia, yet optimal management for lower-risk patients remains undefined, particularly in Asian populations. We retrospectively analyzed 48 patients with lower-risk hMDS (IPSS-R very low/low/intermediate) treated at Tianjin Medical University General Hospital from 2013 to 2021. Patients received cyclosporine A (CsA, n = 16), hypomethylating agents (HMAs, n = 10), low-dose HMAs (LD-HMAs, n = 11), or best supportive care (BSC, n = 11). Responses were assessed by modified IWG criteria, and survival was evaluated by Kaplan-Meier and Cox regression analyses. Median age was 61 years (range 16-84), with 60.4% male. Somatic mutations were present in 64.6%, and PNH clones in 29.2%. Six-month overall response rates were 75.0% for CsA, 70.0% for HMAs, 54.5% for LD-HMAs, and 36.4% for BSC (p = 0.220). CsA achieved significantly longer complete remission (median 75 months) and hematologic improvement durations (p < 0.05). Median overall survival (OS)/progression-free survival (PFS) for CsA were 78.0/76.0 months, compared with 17.0/6.8 for HMAs, 31.0/15.0 for LD-HMAs, and 36.0/15.0 for BSC (p < 0.01). HMAs were associated with increased grade 3-4 infections. CsA provides superior response durability, survival outcomes, and safety compared with other approaches, supporting its use as first-line therapy in lower-risk hMDS. Integration of immune and molecular profiling may refine individualized treatment strategies.

  • Open Access

    A case of acute myeloid leukemia and multiple myeloma is observed to occur simultaneously

    by Shanfeng Hao, Yingqi Li, Huaquan Wang

    Rationale: Cases of acute myeloid leukemia occurring simultaneously with multiple myelomas are rare. To date, only 31 cases have been reported worldwide. The prognosis of these patients is very poor, and it is very important for them to be diagnosed promptly and treated effectively. Patient concerns: A 68-year-old male patient was admitted due to the presence of intermittent nosebleeds accompanied by fever for 10 days, in addition to the development of a right neck mass over 3 days. Diagnoses: Diagnosis of acute monocytic leukemia (high-risk group) was based on morphology, immunophenotyping, histochemical staining, and chromosomal and genetic test results. The patient’s chromosomes were found to be normal, yet next-generation sequencing revealed a TP53 mutation, thus classifying the risk stratification as high risk. The diagnosis of multiple myeloma was diagnosed based on the presence of > 10% myeloma cells and bone marrow biopsy findings suggestive of multiple myeloma. Interventions: Azacitidine 100 mg subcutaneous injection on days 1 to 7, in conjunction with hydrocortisone 50 mg every 12 hours, to treat acute myeloid leukemia in conjunction with multiple myeloma. During this course of treatment, the patient was administered anti-infectious therapy. Outcomes: The patient developed a brain abscess during treatment and passed away 2 months after hospitalization. Lessons: The patient’s disease was severe and rapidly progressive, and comorbid severe infections and consistent comorbid severe pancytopenia posed challenges in managing this disease. It is hoped that more effective targeted therapies can be explored for such patients.


  • Open Access

    UBA1-depleted neutrophils disrupt immune homeostasis and induce VEXAS-like autoinflammatory disease in mice

    by Ge Dong, Jingjing Liu, Wenyan Jin, Hongxi Zhou, Yuchen Wen, Zhiqin Wang, Keyao Xia, Jianlin Zhang, Linxiang Ma, Yunxi Ma, et al.

    Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a hemato-rheumatoid disease caused by somatic UBA1 mutations in hematopoietic stem cells (HSCs). The pathogenic cell type(s) responsible for the syndrome are unknown, and murine models recapitulating the disease are lacking. We report that loss of Uba1 in various mouse hematopoietic cell types resulted in pleiotropic consequences and demonstrate that an approximate 70% loss of Uba1 in neutrophils (NEs) of murine mutants induced nonlethal VEXAS-like symptoms. Depletion of Uba1 in HSCs induced extensive hematopoietic cell loss, whereas depletion of Uba1 in B cells, T cells, or megakaryocytes induced corresponding cell death, but these mutant mice appeared normal. Depletion of Uba1 in monocytes and NEs failed to induce cell death, and the mutant mice were viable. Among the tested models, only depletion of Uba1 in NEs induced autoinflammatory symptoms including increased counts and percentages of NEs, increased proinflammatory cytokines, presence of vacuoles in myeloid cells, splenomegaly, and dermatitis. Residual Uba1 was approximately 30% in the mutant NEs, which disrupted cellular hemostasis. Finally, genetic loss of the myeloid prosurvival regulator Morrbid partially mitigated the VEXAS-like symptoms. The established VEXAS-like murine model will further our understanding and treatment of the newly identified autoinflammatory syndrome prevalent among aged men.